Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the use of novel oral anticoagulants (NOACs) for stroke prevention, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of NOACs for stroke prevention in AF. There were clear practice differences evident, and also the need for greater adherence to the guidelines, especially since guideline adherent management results in better outcomes in AF.
University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham B18 7DH, UK.
Gregory Y H
GY
Lip
Maria Grazia
MG
Bongiorni
Dan
D
Dobreanu
Thorsten
T
Lewalter
Jesper
J
Hastrup Svendsen
Carina
C
Blomström-Lundqvist
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D016903:Drug Monitoring / Q000379:methods; D017723:Drug Utilization Review; D005060:Europe; D019983:Guideline Adherence; D019538:Health Care Surveys; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants
Anticoagulation; Apixaban; Atrial fibrillation; Dabigatran; EHRA survey; EP wire; Guidelines; New oral anticoagulants; Rivaroxaban; Stroke; Warfarin